Similarly, Passaro et al. [58] recently completed the ESMO consensus statements on the management of EGFR mutant NSCLC patients confirming the clinical need of having data that are more consistent to be used in the daily clinic in the absence of randomized prospective trials. Here, EGFR is linked to non-small cell lung carcinoma.